Monthly Dosing of Atacicept in IgAN
← catalyst calendarNCT07020923 · readout ≤ 42 d
Sponsored by Vera Therapeutics, Inc. (industry) · VERA — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
90estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-29 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- IgA Nephropathy (IgAN)
- Berger Disease
Intervention
- Drug: Atacicept — also filed as VT-001
Primary outcome
what the primary-completion date above is the date OFEvaluate the effect of atacicept on Gd-IgA1 in patients with IgAN
measured Up to 24 weeks
Permalink · VERA's whole pipeline · Catalyst calendar · Every registered study · What changed